The main aim of this protocol is to describe the development and validation of an interferon (IFN)-α single molecule array digital Enzyme-Linked ImmunoSorbent Assay (ELISA) assay. This system enables the quantification of human IFN-α protein with unprecedented sensitivity, and with no cross-reactivity for other species of IFN.
Introduction
Type I IFNs are a family of cytokines which play a central role in orchestrating antiviral immune responses. They were first discovered by Isaacs and Lindenmann 60 years ago 1, 2 and it is now known that this heterogeneous family of polypeptides comprises 14 different subclasses (13 IFN-α subtypes and 1 IFN-β). Type I IFNs are essential to the clearance of viral infections, but have also been implicated in the pathology of a variety of human disease states, including the autoimmune disorders systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), and the type I interferonopathies in which constitutive type I IFN-induced signaling results in pathology 3, 4, 5, 6, 7 .
Studying type I IFN protein levels in biological samples has been challenging since its initial identification as an "interfering substance" 1, 2 . Currently, sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA) is the most widely used method for detection of IFN-α protein. Despite being specific, simple, and rapid, type I IFN ELISAs present important limitations, such as limited sensitivity. In addition, the measurement of all IFN-α subtypes requires the use of multiple assays each with their own detection capacity and sensitivity. While there are commercial ELISAs that detect different subtypes of IFN-α, their sensitivity is limited (1.95 pg/mL, 12.5 pg/mL, and 12.5 pg/mL, respectively) which is often insufficient to detect IFN-α protein in biological samples. To overcome this limitation, several biological proxy assays have been developed to quantify type I IFN by measuring induced gene expression or functional activity . In essence single molecule arrays are capable of counting single immunocomplexes and determining an average number of enzymes per bead (AEB). Counting the microwells in which a signal is detected permits quantification/ digitalization of protein molecules, as there is a direct correlation between protein concentration and the ratio between immunocomplexed-beads and a total number of beads present in the femtoliter-sized chambers.
Yeung et al. performed an extensive cross-platform evaluation study using nine different technologies and four cytokine immunoassays with the aim of comparing assay precision, sensitivity, and data correlation across the different platforms 19 . One of the key findings of the study was that single molecule arrays and single molecule counting immunoassay presented the highest sensitivity for detection of cytokines in human serum within the sub-pg/mL concentration range. Single molecule array digital ELISA cytokine assays have been used to study the role of TNF-α and IL-6 in Crohn's disease 20 , IFN-α in interferonopathy and auto-immune patients 7 , and the different post-translationally modified forms of C-X-C motif chemokine 10 (CXCL10) in chronic hepatitis and healthy donors receiving sitagliptin 21, 22 . Other applications include measurement of rhodopsin in patients with diabetic retinopathy 23 ; the study of brain pathologies through serum/plasma measurements of neurofilament light 24 and amyloid-β 1-42 peptide 25 , in the context of multiple sclerosis and Alzheimer's disease, respectively. Single molecule array assays can also be used for improved pathogen detection such as characterization of the HIV viral reservoir 26 , and also for detection of DNA 27 and micro RNAs 28 . A major advantage of the single molecule array technology is this high versatility, as an assay against any analyte of interest can be developed if a specific antibody pair is available. In addition, homebrew assay kits are commercially available, allowing the development of new assays, the protocol of which is detailed in a modified form below.
Here, a detailed description of the development and validation steps for a single molecule array assay is presented that results in enhanced sensitivity for IFN-α protein detection. Antibodies for single molecule array assays should be highly specific, avoiding cross reactivity with related proteins (with species specificity considered if relevant). Ideally, antibodies with a K D smaller than 10 -9 M should be chosen; high affinity ensures strong binding, with the production of a higher signal. The kinetics of the antibody-antigen binding are also important, and fast K on and slow K off will favor antigen-antibody complex assembly. Starting with an antibody pair that has a good performance in classical ELISA, with a limit of detection (LOD) of 1 -100 pg/mL, increases the chances of obtaining a highly sensitive single molecule array assay. Chang and colleagues performed detailed kinetic studies of the biomolecular interactions occurring at every single step, proposing a set of equations to predict analytical sensitivity 18 . They showed that single molecule array digital ELISA appears to be effective within a broad range of antibody affinities (KD~10 −11 -10 −9 M), as well as that signal generation is more dependent on the on-rate of such antibodies.
To utilize high affinity antibodies we took advantage of antibodies isolated from patients with the autoimmune polyendocrinopathy syndrome type 1/autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APS1/APECED) 29 . For reasons that are not yet understood, the large majority of AIRE-deficient individuals develop a core set of high-avidity antibodies against all IFN-α subtypes 29 , and we selected two anti-IFN-α antibody clones of complementary binding affinities for the different IFN-α subtypes, as estimated by IC 50 values. The combination of these unique high-affinity antibodies with single molecule array technology enabled the direct quantification of IFN-α at attomolar (fg/mL) concentrations. Such ultrasensitive IFN-α protein detection will contribute to a better understanding of the nature, regulation and biological impact of the IFN-induced response in different disease settings.
Protocol

Selection of Antibodies
1. Before beginning the protocol review all key steps ( Table 1 ) and select optimum antibodies.
NOTE: For this protocol high affinity anti-IFN-α antibodies -the IC50 of which are described in Table 2 were selected. Preferentially, choose a pair that works well with conventional ELISA.
Conjugation of Capture Antibody to Paramagnetic Beads and Testing of Different Concentrations
NOTE: Always keep Bead Conjugation Buffer (BCB) and Bead Wash Buffer (BWB) on the ice during the antibody conjugation process.
1. Capture Antibody Buffer Exchange 1. Take initial quantities of anti-IFN-α antibody A to test 3 different bead conjugations ratios (0.038 mg/mL, 0.075 mg/mL, and 0.3 mg/mL). NOTE: Low antibody coating concentrations can be beneficial if the assay presents a high background signal. Initial antibody quantity should account for an estimated 30% loss during the buffer exchange process. According to manufacturer's instructions and in order to reduce initial background, concentrations of 0.05 mg/mL, 0.1 mg/mL, and 0.3 mg/mL were tested, although these exact values were often not obtained due to the aforementioned variable loss in the buffer exchange process. 2. Add the required volume of the antibody into a filter column together with BCB, up to 500 µL. 3. Centrifuge the columns at >10,000 x g for 5 min and discard the flow-through. 4 . Wash the column twice by adding a total volume of 450 µL of BCB followed by centrifugation at >10,000 x g for 5 min and discard the flow through. 5. Place the filter column containing the antibody into a clean microcentrifuge tube upside down -the open part of the column facing the inside of the new tube -and centrifuge at 800 x g for 1 min. NOTE: This step will allow collection of the cleaned antibody. No buffer addition is required for this step. 6. Wash the membranes with 50 µL BCB and centrifuge at 800 x g for 1 min as in 2.1.5.
. The single molecule array analyzer machine is controlled by software that allows to run assay standardizations, to perform sample quantifications, to modify external parameters (bead, detector, SBG, RGP concentrations; sample dilutions...) and internal parameters (number of steps, incubation times...) to achieve optimal assay conditions, and can also be used to calculate results (background, LOD, quantities). For the setup of the single molecule array analyzer and to calculate the reagent volumes required for each round of optimization, see manufacturer's instructions. Perform the first rounds of optimization using a 2-step configuration.
1. Test combinations of capture antibody-conjugated beads and biotinylated detection antibody in both configurations.
1. Test combinations of the three different anti-IFN-α A capture antibody concentrations with the two different anti-IFN-α B biotinylation ratios as detection and capture antibodies, and vice versa (Figure 1) by selection of the appropriate conditions in the analyzer software. 2. Choose the most sensitive combination, that is, the conditions that offer the lowest LOD, and use it for further steps NOTE: Figure 1 shows how a 0.3 mg/mL anti-IFN-α A antibody bead concentration and a biotin:antibody ratio of 30:1 with the anti-IFN-α B antibody resulted in the highest sensitivity, as evidenced by an LOD of 11.6 fg/mL. (See Supplementary Table 1) . This combination will be used for all future steps. Notice that the great sensitivity achieved with this particular assay before any rounds of optimization. NOTE: Figure 3 shows that detector 0.3 µg/mL and SBG 150 pM were the conditions that showed the optimal LOD. These conditions also gave low background levels and medium amplitude, a behavior that produces good standard deviation (SD) values (Supplementary Table 3 ). Typical concentrations range between 0.1 -1 µg/mL for the detection antibody and 50 -200 pM for SBG, although higher concentrations (e.g. up to 300 pM) of the latter might be required. It is important to avoid conditions that will render backgrounds higher than 0.02 AEB. Increasing the concentration of the detector monoclonal antibody (mAb) or SBG will enhance both signal response and background. However, if the increment in signal surmounts the change in background, the LOD will improve. A situation can arise in which a decrease in background allows better discrimination between low calibrators. 4. Additional optimization steps 1. If the required sensitivity has not been achieved, test different incubation times for the different steps using the preconfigured options in the analyzer software. 2. If the assay is not sensitivity enough, optimize the number of beads per assay using the preconfigured options in the analyzer software. Step
Considerations Reference
Target different epitopes High affinity
Antibody pair choice
Fast K on / Slow K off Table 2 2. Antibody pair orientation Table 2 : Pan-alpha antibody selection. IC50 (ng/mL) determined using the interferon-stimulated response element (ISRE)-Luciferase neutralization assay. Table shows IC50 A) ratios were also tested for both configurations. Saturation (Sat). Orange: AEB values that were used for LOD calculation; these concentrations were considered blank as the AEB values remained steady. LOD was calculated as Mean Blank + 3SD. Please click here to download this file.
Supplementary Table 2 : Test of 2 vs 3-step configuration. The 2 and 3 -step configurations were assessed using IFNα-2c as antigen. AEB values as well as signal/background rations (S/B) are shown for both conditions. Please click here to download this file. 
Supplementary
Discussion
Herein, we described the development and validation of a highly reproducible, ultrasensitive single molecule array digital ELISA for direct quantification of IFN-α protein in human samples (steps summarized in Table 1 ). One of the most critical steps in the development of the assay is the choice of antibody pair 16 , with the characteristics in terms of kinetics and epitope binding being key to a successful assay. It is important to avoid the use of paired monoclonal antibodies that target the same epitope or that cause steric impediment. Polyclonal antibodies could be used as detection antibodies to overcome such limitations. If at any given step the desired sensitivity is not achieved, further optimization possibilities should be considered. This may include the use of alternative antibody pairs, changes in parameters such as protein type (e.g. BSA < casein), pH (6.0 -8.5), ionic strength, buffering capacity (e.g. NaCl and phosphate concentrations), carrier beads, and/or presence of surfactants. A wide range of parameters con be optimized when developing a single molecule array assay. However, overall, conditions that give high signal:background ratios and minimal LODs are the ones preferred (see Figure 1, Figure 2, and Figure 3 ).
Regarding specificity, the IFN-α assay showed no cross reactivity for any other IFNs tested (β, γ, λ1, λ2, ω) (Figure 4a ) and was capable of detecting all 13 IFN-α subtypes (Figure 4b) . However, the assay showed a lower affinity for the IFN-α2 subtype, (Figure 4b and Supplementary Table 4 ). Interestingly, different sensitivities for the different classes of IFN-α2 (a, b, c) were also observed, which may be due to distinct manufacturing procedures or different amino acid sequences, as the IFN-α2 subtypes were obtained from different commercial suppliers. With this sole exception, all the IFN-α species gave very similar responses. The specificity of the assay was further demonstrated by pre-treatment of the samples with the anti-IFN-α A clone, which abrogated the signal (Figure 6 and Supplementary Table 6 ).
One of the main advantages of this technology is that any analyte of interest can potentially be targeted 16 . Furthermore, different biological specimens can be tested, such as serum, plasma, cerebrospinal fluid, cellular lysates, culture supernatants 31 and even breath 32 . Usually, a 1:3 dilution of plasma is performed to avoid potential clogging of the single molecule array analyzer. However, the analyte of interest could be present at very low concentrations in the relevant biological sample and higher concentrations of sample might be required (depending on assay sensitivity) 33 . Although there is potential for multiplexing while maintaining good sensitivity 34 , it is a more challenging process and assays for measuring greater than 6 proteins within the same experiments have yet to be developed 35 .
The ability to detect and quantify cytokines and other biological relevant proteins at such low concentrations opens up a whole new range of applications 33, 36 . It is well known that numerous proteins exert their effects even at very low concentrations, which up until now were below the limit of detection of the best ELISAs 37 . While other immunoassay technologies offer advantages over conventional ELISA 19 , we demonstrate here that single molecule array digital ELISA is a reproducible and robust platform for the ultrasensitive detection of low concentration cytokines in human samples. As such, this technology offers enormous potential for biomarker discovery and improved patient management of a wide range of diseases.
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